ContextVision has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession.
ContextVision delivered the Company’s best ever second quarter within Medical Imaging. Initial response from the ongoing clinical trials with the Company’s first digital pathology product, INIFY Prostate, are very promising.
ContextVision today reports its first quarter results for 2021. The quarter saw strong and promising progress within digital pathology and the company’s first product, INIFY Prostate Screening. While the ongoing pandemic slowed sales slightly, solid financials – paired with close dialogues with present and prospective clients – provide a positive outlook.
STOCKHOLM – April 7, 2021 – Please find ContextVision’s Annual Report 2020 and Remuneration Report 2020 attached. The reports can also be found on the company’s website: www.contextvision.se Printed copies of the reports will be distributed upon request by e-mail: For inquiries, please contact CFO Ann-Charlotte Linderoth E-mail: About ContextVision ContextVision is […]
ContextVision, today reports its fourth quarter and full year 2020 results. Total sales 2020 reached 94.7 MSEK (95.3), which matches the record year 2019 if adjusted for currency exchange effect – a solid achievement much related to a strong start of the year. Total EBITDA ends at 25.5 MSEK and operating result reached 15.5 MSEK.
ContextVision’s third quarter sees a recovery in sales and market entry in digital pathology is on track
ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its third quarter.
ContextVision today reports a progressive second quarter. INIFY® Prostate Screening – the company’s first decision support tool in a planned digital pathology portfolio – was granted CE-mark status, paving the way for a strong entry into the fast-growing digital pathology market. In addition, the company continues to spearhead the image enhancement market with its new next-generation ultrasound product, Rivent®.
ContextVision today announced the strengthening of its board of directors. Martin Ingvar, Professor of Integrative Medicine at Karolinska Institute Sweden and founding member of International Consortium for Health Outcome Measurements (ICHOM), was elected as new member of the board at the annual general meeting.
ContextVision Sees Strongest Quarter Ever with Record Sales and Product Momentum within Digital Pathology
STOCKHOLM – April 23, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced record sales and EBITDA, mainly driven by the company’s medical imaging business, despite the current global challenges. ContextVision’s first digital pathology solution continues to accelerate toward market availability. Medical Imaging Sales in Q1 ended […]